ACTRN12619000381189终止未知
Evaluating a phase-based intervention for the treatment of PTSD symptoms in refugees .
Professor Angela Nickerson0 个研究点目标入组 71 人开始时间: 2019年3月11日最近更新:
适应症
试验速览
- 阶段
- 未知
- 状态
- 终止
- 发起方
- 入组人数
- 71
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomised controlled trial
- 主要目的
- Treatment
- 盲法
- Blinded (masking used)
入排标准
- 年龄范围
- 18 Years 至 o limit（—）
- 性别
- All
入选标准
- •Inclusion criteria
- •(i) Aged over 18 years old
- •(ii) A refugee or asylum-seeker background
- •(iii) Fluent and literate in Arabic, Farsi or Dari
- •(iv) Meet criteria for PTSD diagnosis (according to DSM-5)
- •(v) If on concurrent pharmacological treatment they will be on a stable dose for one month prior to completing their initial assessment
排除标准
- •(i) Individuals experiencing active suicidality (intent and/or a previous suicide attempt in the past three months)
- •(ii) Active psychosis or alcohol/substance dependence
- •(ii) Moderate to severe traumatic brain injury
研究者
相似试验
进行中（未招募）
1 期
A phase IV interventional study to assess the disease-modifying effect of long-term treatment with tildrakizumab in adult patients with moderate-to-severe plaque psoriasisModerate to severe plaque psoriasisMedDRA version: 20.0Level: LLTClassification code 10071117Term: Plaque psoriasisSystem Organ Class: 100000004858EUCTR2019-003218-15-PLAlmirall S.A.47
已完成
不适用
Implementation and evaluation of an intervention to improve medical care for the homelessMulitmorbidity of the homelessDRKS00015455Sektion für Versorgungsforschung und Rehabilitationsforschung, Universitätsklinikum Freiburg689
招募中
不适用
The effect of interventions on participation in colorectal cancer screeningCondition 1: Colon Cancer. Condition 2: Rectom Cancer.Malignant neoplasm of colon, unspecifiedMalignant neoplasm of rectumC18.9IRCT20131117015426N8Shiraz University of Medical Sciences200
招募中
1 期
A phase 3b, interventional, adaptive, clinical trial to evaluate the efficacy and safety of tralokinumab 300 mg every second week monotherapy compared with placebo in subjects with moderate-to-severe atopic hand eczema who are candidates for systemic therapy (ADHAND)Atopic dermatitis and moderate-to severe atopic hand eczemaMedDRA version: 21.1Level: LLTClassification code: 10003639Term: Atopic dermatitis Class: 10040785MedDRA version: 21.1Level: LLTClassification code: 10003641Term: Atopic eczema Class: 10040785CTIS2022-502653-34-01EO PHARMA A/S402
招募中
3 期
Outpatient Ifosfamide, Etoposide plus Rituximab (R-IE) for salvage in patients > 60 years with relapsed or refractory CD20 positive diffuse large B-cell lymphoma who are not candidates for stem cell transplant studyRelapsed or refractory CD20 positive diffuse large B-cell lymphomaCancer - Lymphoma (non Hodgkin's lymphoma) - High grade lymphomaACTRN12606000373572Roche40